A detailed history of Benchmark Investment Advisors LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Benchmark Investment Advisors LLC holds 2,275 shares of SRPT stock, worth $270,656. This represents 0.2% of its overall portfolio holdings.

Number of Shares
2,275
Previous 2,275 -0.0%
Holding current value
$270,656
Previous $359,000 20.89%
% of portfolio
0.2%
Previous 0.26%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$113.33 - $163.85 $11,899 - $17,204
-105 Reduced 4.41%
2,275 $359,000
Q1 2024

May 15, 2024

SELL
$93.7 - $141.53 $26,704 - $40,336
-285 Reduced 10.69%
2,380 $308,000
Q4 2023

May 15, 2024

BUY
$67.31 - $124.76 $179,381 - $332,485
2,665 New
2,665 $256,000
Q3 2023

Nov 14, 2023

SELL
$102.5 - $123.59 $33,825 - $40,784
-330 Reduced 9.08%
3,305 $400,000
Q2 2023

Aug 11, 2023

SELL
$106.4 - $157.19 $532 - $785
-5 Reduced 0.14%
3,635 $416,000
Q1 2023

May 12, 2023

SELL
$117.53 - $155.99 $14,456 - $19,186
-123 Reduced 3.27%
3,640 $501,000
Q4 2022

Feb 21, 2023

SELL
$100.86 - $132.13 $12,103 - $15,855
-120 Reduced 3.09%
3,763 $487,000
Q3 2022

Nov 14, 2022

BUY
$75.71 - $119.24 $8,328 - $13,116
110 Added 2.92%
3,883 $429,000
Q2 2022

Aug 08, 2022

SELL
$62.69 - $88.44 $9,403 - $13,266
-150 Reduced 3.82%
3,773 $283,000
Q1 2022

May 16, 2022

SELL
$63.15 - $90.42 $4,420 - $6,329
-70 Reduced 1.75%
3,923 $306,000
Q4 2021

Feb 16, 2022

BUY
$77.28 - $99.42 $308,579 - $396,984
3,993 New
3,993 $360,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Benchmark Investment Advisors LLC Portfolio

Follow Benchmark Investment Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benchmark Investment Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Benchmark Investment Advisors LLC with notifications on news.